Hepatic Function in Liver Cancer Patients
Author Information
Author(s): I. Virgolini, C. Muller, W. Klepetko, P. Angelberger, H. Bergmann, J. O'Grady, H. Sinzinger
Primary Institution: University of Vienna
Hypothesis
Does the in vivo HBP density measured by 99mTc-NGA scintigraphy change in patients with primary or secondary liver cancer?
Conclusion
The study found that patients with hepatoma or liver metastasis have significantly decreased HBP density, indicating reduced hepatic function.
Supporting Evidence
- Patients with hepatoma had an HBP concentration of 0.38 ± 0.06 μmol/l.
- Patients with liver metastasis had an HBP concentration of 0.4 ± 0.1 μmol/l.
- Normal liver tissue showed significantly higher HBP density compared to malignant tissues.
Takeaway
This study shows that a special tracer can help doctors see how well the liver is working in cancer patients.
Methodology
The study involved measuring HBP density in liver tissue samples from patients undergoing surgery and comparing in vivo and in vitro binding of a specific tracer.
Limitations
The study may not account for all factors affecting liver function and relies on a specific tracer's binding characteristics.
Participant Demographics
Patients aged 44-81 years undergoing surgery for various cancers.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website